66. IgA腎症 IgA nephropathy Clinical trials / Disease details


臨床試験数 : 275 薬物数 : 258 - (DrugBank : 82) / 標的遺伝子数 : 36 - 標的パスウェイ数 : 140

  
5 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1ChiCTR-TRC-13003038
2013-01-012013-01-11Mizoribine for the Treatment of Pediatric IgA NephropathyMizoribine for the Treatment of Pediatric IgA Nephropathy with Moderate Proteinuria--An open, prospective, random, multicenter study IgA nephropathyMZR:mizoribine tablet 4 mg/kg a day (not more than 150 mg/d), qd, po + Dipyridamole, 3 mg/kg a day (not more than 25 mg at a time), tid, po;CVT:Lotensin, 0.2 mg/kg a day (not more than 10 mg/d), qd, po + + Dipyridamole, 3 mg/kg a day (not more than 25 mg at a time), tid, po;Peking University First HospitalNULLCompleted618BothMZR:60;CVT:60;China
2ChiCTR-ONC-10001124
2011-01-012010-12-04The effect and safety of mizoribine for IgA Nephropathy in childrenThe effect and safety of mizoribine for IgA Nephropathy in children IgA nephropathy1:mizoribine 3~5mg/kg.d;Nanjing general hospital of Nanjing military commandNULLCompleted516Both1:30;China
3JPRN-UMIN000000593
2006/11/0105/02/2007Randomized controlled trial of mizoribine for progressive IgA nephropathyRandomized controlled trial of mizoribine for progressive IgA nephropathy - Randomized controlled trial of mizoribine for progressive IgA nephropathy IgA nephropathy with moderate to severe histological alterationsMethylprednisolone pulse therapy followed by oral prednisolone administration
Methylprednisolone pulse therapy followed by oral prednisolone and mizoribine administration
West Japan Study Group for Therapy of IgA NephropathyNULLComplete: follow-up complete15years-old60years-oldMale and Female120Not selectedJapan
4JPRN-C000000363
2001/08/0114/05/2007A combination of prednisolone and mizoribine and a combination of prednisolone, mizoribine, warfarin and dipyridamole for IgA nephropathy with diffuse mesangial prolideration in children:A randomized controlled trial of efficacy and safetyA combination of prednisolone and mizoribine and a combination of prednisolone, mizoribine, warfarin and dipyridamole for IgA nephropathy with diffuse mesangial prolideration in children:A randomized controlled trial of efficacy and safety - A combination of prednisolone and mizoribine and a combination of prednisolone, mizoribine, warfarin and dipyridamole: A randomized controlled trial(JPIGANTS01) IgA nephropathy in childrenprednisolone+mizoribine for 2 years
prednisolone+mizoribine+warfarin+dipyridamole for 2 years
The Japanese Pediatric IgA Nephropathy ofTreatment Study GroupNULLComplete: follow-up complete2years-old18years-oldMale and Female80Not selectedJapan
5JPRN-C000000375
1998/08/0101/04/2006A combination of prednisolone, mizoribine, warfarin and dipyridamole for IgA nephropathy with nephrotic syndrome and diffuse mesangial proliferation in children.A combination of prednisolone, mizoribine, warfarin and dipyridamole for IgA nephropathy with nephrotic syndrome and diffuse mesangial proliferation in children. - A combination of prednisolone, mizoribine, warfarin and dipyridamole for IgA nephropathy with nephrotic syndrome and diffuse mesangial proliferation in children. IgA nephropathy in childrenprednisolone+mizoribine+warfarin+dipyridamole for 2 yearsThe Japanese Pediatric IgA Nephropathy of Treatment Study GroupNULLComplete: follow-up complete2years-old18years-oldMale and Female20Not selectedJapan